Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Interest Expenses (2023 - 2024)

Corbus Pharmaceuticals Holdings has reported Interest Expenses over the past 3 years, most recently at $930000.0 for Q4 2023.

  • For Q4 2023, Interest Expenses changed N/A year-over-year to $930000.0; the TTM value through Dec 2023 reached $2.9 million, changed N/A, while the annual FY2024 figure was $1.9 million, 51.48% down from the prior year.
  • Interest Expenses for Q4 2023 was $930000.0 at Corbus Pharmaceuticals Holdings, down from $980000.0 in the prior quarter.
  • Over five years, Interest Expenses peaked at $1.0 million in Q2 2023 and troughed at $930000.0 in Q4 2023.